Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.265
-0.055 (-2.37%)
Mar 31, 2025, 3:34 PM EDT - Market open

Grace Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Grace Therapeutics stock has a target of 12, which predicts an increase of 429.80% from the current stock price of 2.27.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $12 $12 $12 $12
Change +429.80% +429.80% +429.80% +429.80%
* Price targets were last updated on Feb 18, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Grace Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Feb '25Mar '25
Strong Buy 11
Buy 00
Hold 00
Sell 00
Strong Sell 00
Total 11

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$12
Strong Buy Reiterates $12 +429.80% Feb 18, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.95
from -1.35
EPS Next Year
-1.28
from -1.95
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2025 FY 2026
Period Ending Mar 31, 2020 Mar 31, 2021 Mar 31, 2022 Mar 31, 2023 Mar 31, 2024 Mar 31, 2025 Mar 31, 2025 Mar 31, 2026
Revenue
-196.00K------
Revenue Growth
--------
EPS
-14.48-7.96-1.60-5.71-1.35-1.95-1.28-0.95
EPS Growth
--------
Forward PE
--------
No. Analysts -----455
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202520262027
High n/a 905,027 23.6M
Avg n/a 439,579 12.0M
Low n/a n/a 1.3M

Revenue Growth

Revenue Growth 202520262027
High - -
5,273.5%
Avg - -
2,634.9%
Low - -
203.9%

EPS Forecast

EPS 202520262027
High -1.31 -1.79 -0.57
Avg -1.28 -1.74 -0.63
Low -1.23 -1.67 -0.68

EPS Growth

EPS Growth 202520262027
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.